ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Market cap

<< Previous

Bullboard Posts

Next >>

Comment by bball67on May 13, 2022 4:04pm

125 Views

Post# 34682845

RE:RE:RE:RE:RE:Market cap

Of course the year over year expenses went up. It is not a low bar, results and progress are in English on four or 5 pages. This is a very sellable opportunity. I was a CFO for a public company and spent a lot of time on the phone and in Boston and NY selling our story. Time was spent at conferences, CEO and CFO. Maybe a part time CFO is not cut out for selling a very good story. A CFO who believes can make a huge difference, followed by results. The role of CFO has evolved over the last 20years. I believe the bear market in Biophatma has bottomed. This story is compelling!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China